A recent animal study found that a patented collagen from Bioiberica in combination with chondroitin sulphate, glucosamine hydrochloride and hyaluronic acid protected the structural integrity of joints in subjects with osteoarthritis.
A recent animal study1 found that a patented collagen (b-2Cool) from Bioiberica in combination with chondroitin sulphate, glucosamine hydrochloride and hyaluronic acid (Bioiberica’s Mobilee) protected the structural integrity of joints in subjects with osteoarthritis. In the prospective, randomized, double-blind, experimental study, 54 ten-week old New Zealand white rabbits were divided into three groups receiving either placebo (control), a combination ofchondroitin sulphate, glucosamine hydrochloride, and hyaluronic acid (Group 1), or a combination of chondroitin sulphate, glucosamine hydrochloride, hyaluronic acid, and native type II collagen (Group 2). Osteoarthritis was induced by anterior cruciate ligament section.
Results showed that while all the rabbits developed degenerative changes associated with osteoarthritis, the rabbits in Group 2 had cartilage appearance that was much closer to that of healthy cartilage. Compared to placebo, both Group 1 and Group 2 has significantly better matrix staining, cartilage structure, chondrocyte density and synovial membrane, indicating that these groups did not show the degree of degenerative changes observed in the Control group. Overall, the joints of rabbits in Group 2 were healthier than that of Group 1, but Group 1 still had significantly healthy joints than the control group.
“This study is a key development in Bioiberica’s joint health research. It complements previous research by providing additional validation for the benefits of using native type II collagen in innovative mobility solutions and allows Bioiberica to further position b-2Cool as a trusted ingredient for effective joint health formulations,” said Jaume Reguant, director of healthcare at Bioiberica, in a press release. “As younger, health-conscious consumers take more of an interest in their mobility, the joint health market must evolve to appeal beyond the senior population.”
“These audiences are interested in comprehensive solutions that target overall mobility and help them live life to the fullest as they age,” Reguant adds. “These new results show the effectiveness of combining Bioiberica’s ingredients for joint health and opens up new opportunities for manufacturers looking to expand their portfolio and explore more holistic mobility offerings for consumers.”